Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Onartuzumab |
Synonyms | |
Therapy Description |
Onartuzumab is a monovalent antibody that binds MET and inhibits MET/HGF signaling, potentially resulting in decreased tumor growth (PMID: 23882082, PMID: 30472556). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Onartuzumab | MetMAb|RO5490258|OA-5D5 | MET Antibody 31 | Onartuzumab is a monovalent antibody that binds MET and inhibits MET/HGF signaling, potentially resulting in decreased tumor growth (PMID: 23882082, PMID: 30472556). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01456325 | Phase III | Erlotinib Onartuzumab | A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) | Completed | USA | POL | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 10 |
NCT01662869 | Phase III | Onartuzumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric) | Completed | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 11 |